Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval-Reference-Cited by-同舟云学术

Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval

Published:2019-07-01 Issue:7 Volume:179 Page:906
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Gyawali Bishal¹²,Hey Spencer Phillips¹,Kesselheim Aaron S.¹

Affiliation:

1. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

2. Department of Oncology, Department of Public Health Sciences, and Division of Cancer Care and Epidemiology, Queen’s University, Kingston, Ontario, Canada

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

http:///jamainternalmedicine/article-pdf/179/7/906/17690741/jamainternal_gyawali_2019_oi_190018.pdf

Reference44 articles.

1. Individual- and trial-level surrogacy in colorectal cancer.;Buyse;Stat Methods Med Res,2008

2. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.;Paoletti;J Natl Cancer Inst,2013

3. Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.;Shitara;Gastric Cancer,2014

4. Surrogate outcomes in clinical trials: a cautionary tale.;Svensson;JAMA Intern Med,2013

5. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?;Kemp;BMC Med,2017

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval;Journal of Clinical Epidemiology;2024-10

2. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

3. Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility;Future Pharmacology;2024-09-05

4. Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval;Journal of Pharmaceutical Innovation;2024-09-04

5. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09